DrugsNews.net

Drugs Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Onco News

Search results for "Jakafi"

Ruxolitinib ( Jakafi ) is an oral, selective inhibitor of Janus kinases 1 and 2 ( JAK1 and JAK2 ). Ruxolitinib, brand name Jakafi, is indicated for treatment of patients with intermediate or high-risk ...


The U.S. Food and Drug Administration ( FDA ) has approved Jakafi ( Ruxolitinib ) for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. Jakafi is the f ...